Amrubicin for treating elderly and poor-risk patients with small-cell lung cancer

International Journal of Clinical Oncology

Volumn 15, Issue 5, 2010, Pages 447-452

  Igawa, Satoshi ^a   Ryuge, Shinichiro ^a   Fukui, Tomoya ^a   Otani, Sakiko ^a   Kimura, Yuka ^a   Katono, Ken ^a   Takakura, Akira ^a   Kubota, Masaru ^a   Mitsufuji, Hisashi ^a   Katagiri, Masato ^b   Yanase, Nobuo ^b   Masuda, Noriyuki ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KITASATO UNIVERSITY   (Japan)

Author keywords

Amrubicin; Elderly; First line; Poor risk; SCLC

Indexed keywords

ALANINE AMINOTRANSFERASE; AMRUBICIN; ASPARTATE AMINOTRANSFERASE; CREATININE; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEALTH STATUS; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOPENIA; LUNG SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHLEBITIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 78149360004     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-010-0085-2     Document Type: Article

References (18)

1. T Morita 2007 A statistical study of lung cancer in the annual of pathological autopsy cases in Japan, from 1958 to 1997, with reference to time trends of lung cancer in the world Jpn J Cancer Res 93 15 23
2. H Okamoto K Watanabe Y Nishiwaki, et al. 1999 Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer J Clin Oncol 17 3540 3545 1:CAS:528:DyaK1MXnvVGltLw%3D 10550152
3. RL Souhami SG Spiro RM Rudd, et al. 1997 Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy J Natl Cancer Inst 89 577 580 1:CAS:528: DyaK2sXivFensL0%3D 10.1093/jnci/89.8.577 9106647
4. N Murray C Grafton A Shah, et al. 1998 Abbreviated treatment for elderly, infirm, or noncompliant patients with limited-stage small-cell lung cancer J Clin Oncol 16 3323 3328 1:CAS:528:DyaK1cXmvFGrtbo%3D 9779708
5. H Okamoto K Watanabe H Kunikane, et al. 2007 Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702 Br J Cancer 97 162 169 1:CAS:528:DC%2BD2sXnsFaqsLw%3D 10.1038/sj.bjc.6603810 17579629 (Pubitemid 47057464)
6. K Ishizumi 1987 Stereospecific total synthesis of 9-aminoanthracyclines: (+)-9-amino-9-deoxydaunomycin and related compounds J Org Chem 52 4477 4485 1:CAS:528:DyaL1cXnsFOmtg%3D%3D 10.1021/jo00229a010
7. M Hanada 1998 A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex Jpn J Cancer Res 89 1229 1238 1:CAS:528:DyaK1cXnvFygs7Y%3D 9914793
8. T Yamaoka M Hanada S Ichii, et al. 1998 Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells Jpn J Cancer Res 89 1067 1073 1:CAS:528:DyaK1cXnt1Oju7s%3D 9849587
9. S Morisada Y Yanagi T Noguchi, et al. 1989 Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts Jpn J Cancer Res 80 69 76 1:CAS:528:DyaL1MXhs1Glur8%3D 2496061
10. T Noda T Watanabe A Kohda, et al. 1998 Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs Investig New Drugs 16 121 128 1:CAS:528:DyaK1cXnvVOmu7Y%3D 10.1023/A:1006088907271 (Pubitemid 28495213)
11. T Yana S Negoro M Takada, et al. 2007 Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study Investig New Drugs 25 253 258 1:CAS:528:DC%2BD2sXltlartr0%3D 10.1007/s10637-006-9012-9 (Pubitemid 46774694)
12. A Inoue K Yamazaki M Maemondo, et al. 2006 A phase I study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer J Thorac Oncol 1 551 555 10.1097/01243894-200607000-00009 17409916 (Pubitemid 47181403)
13. S Onoda N Masuda T Seto, et al. 2006 Amrubicin for treatment of refractory or relapsed small-cell lung cancer: a phase II thoracic oncology research group study 0301 J Clin Oncol 24 5448 5453 1:CAS:528: DC%2BD2sXisVSitQ%3D%3D 10.1200/JCO.2006.08.4145 17135647 (Pubitemid 46623179)
14. S Igawa N Yamamoto S Ueda, et al. 2007 Evaluation of the recommended dose and efficacy of amrubicin as second- and third-line chemotherapy for small cell lung cancer J Thorac Oncol 2 741 744 10.1097/JTO.0b013e31811f46f0 17762341 (Pubitemid 47357529)
15. Kato T, Nokihara H, Ohe Y (2006) Phase II trial of amrubicin in patients with previously treated small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 24:abst 7061
16. WK Evans A Radwi E Tomiak DM Logan H Martins DJ Stewart G Goss JA Maroun S Dahrouge 1995 Oral etoposide and carboplatin. Effective therapy for elderly patients with small cell lung cancer Am J Clin Oncol 18 149 155 1:STN:280:DyaK2M3gvVKmsg%3D%3D 10.1097/00000421-199504000-00011 7534977
17. E Quoix JL Breton C Daniel, et al. 2001 Etoposide phosphate with carboplatin in the treatment of elderly patients with small-cell lung cancer: a phase II study Ann Oncol 12 957 962 1:STN:280:DC%2BD3MvnvVehtg%3D%3D 10.1023/A:1011171722175 11521802 (Pubitemid 32725769)
18. T Sawa T Yana M Takada, et al. 2006 Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial Investig New Drugs 24 151 158 1:CAS:528:DC%2BD28Xktlertr4%3D 10.1007/s10637-006-5937-2 (Pubitemid 43723907)